President Trump believes a COVID-19 vaccine could be ready before the end of the year. He is also optimistic that on November 3, 2020, U.S. The vaccine can be obtained at the time of election. Is this just wishful thinking? Probably not.
U.S. The Food and Drug Administration (FDA) recently scheduled an advisory committee meeting on October 22, 2020, to “discuss the development, authorization, and / or licensure of the vaccine prescribed to prevent COVID-19.” The agency also said it was “ready to schedule additional meetings of the committee quickly upon proper submission of any requests.” In addition, FDA Commissioner Stephen Heane said in an interview Financial Times That the Covid-1 vaccine is ready for Emergency Use of the Vaccine (EUA) just before the completion of that phase testing.
Add to that all, and we’ve got a real chance that one or more coronavirus vaccines will be available in the U.S. by the end of 2020. Can be found in. But which?
Image Source: Getty Images.
1. Pfizer
Pfizer (NYSE: PFE), With his German partner Biotech (Nasdaq: BNTX), Appears to be a potential company to bring the coronavirus vaccine in the next four months. Both the companies started the clinical trial of phase 2/3 of their main candidate BNT 162B2 on July 27.
This major study will not be rolled out until the end of 2020. However, Pfizer and Bioentech have stated publicly that they are on track to file for regulatory review “in early October 2020.” Said Pfizer CEO Albert Borla W. Washington Post“We will go for regulatory approvals in October.”
Don’t expect full FDA approval for BNT162b2 this year. However, based on FDA Commissioner Hehn’s comments, it would not be surprising if emergency use for Pfizer and Bioentech vaccines is allowed – the 2/3 phase study assumes well. Both companies are set to supply up to 100 million doses by the end of 2020.
2. AstraZeneca
AstraZeneca (NYSE: AZN) U.S. before the end of the year. Comes out as the second largest drug manufacturer with a very good chance of introducing its Covid-19 vaccine. The British pharmaceutical company and its partner, Oxford University, recently began studying US Phase 3 of the vaccine candidate AZD1222 in all adult groups.
Last week, this Financial Times The Trump administration is reportedly evaluating the possibility of authorizing fast-tracking emergency use of AstraZeneca’s COVID-19 vaccine candidate. The company declined to discuss any authorization with the U.S. government for AZD1222, calling any speculation “premature.”
However, this view does not seem unrealistic. AstraZeneca struck a deal earlier this year to supply at least 300 million doses of its Covid-19 vaccine to the U.S. in September 2020. The company is also committed to supplying 100 million doses to the UK starting in September.
3. Modern
Modern (Nasdaq: MRNA) COVID-19 is the only other company with a vaccine candidate in late-stage testing that is not based in China or Russia. Biotech began studying Phase 3 of MRNA-1273 on February 27.
How quickly can MRNA-1273 be prepared for FDA emergency use approval? Moder CEO Stephen Bensell said in an interview with CNBC in July that late-stage results could be available in October under a “really optimistic outlook” or possibly in November. If true, the company could be secured by the FDA EU before the end of the year.
Together with Moderna Cat Lent U.S. To produce the initial 100 million doses of MRNA-1273 for the market. The company expects to begin shipping this dose sometime in the third quarter of 2020.
The biggest winner?
If any of these COVID-19 vaccine candidates prove to be safe and effective and the U.S. Launches in, the biggest winner of all will be the Americans who are ready to end the epidemic.
Which company will be the biggest winner, however, depends on how you define the winner.
Pfizer and Bioentech are the first to receive the most money. If UNT162B2 obtains FDA approval or emergency use approval, U.S. The government will pay both drug manufacturers 1. 1.95 billion for 100 million doses. That’s a total of more than 25 1.525 billion that would go to the U.S. to supply 100 million doses of moderna. Will get from. AstraZeneca The government has already committed up to 1. 1.2 billion, including the supply of at least 300 million doses of AZD1222, although the company has promised not to profit from its vaccine during the epidemic.
However, the biggest winner in terms of stock performance will be Motera Moderna. The company is much smaller than Pfizer and AstraZeneca. While Moderna is bigger than Bioentech, it doesn’t have a partner who will take a big chunk of any money made from its vaccine. Sure, biotech stock has risen this year. But if MRNA-1273 is expected to hit the U.S. in the next few months. If launched in, shares of Moderna will almost certainly go much higher.
